These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11361938)

  • 1. Warning against rechallenge with abacavir.
    AIDS Patient Care STDS; 1998 Mar; 12(3):229. PubMed ID: 11361938
    [No Abstract]   [Full Text] [Related]  

  • 2. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaphylaxis after rechallenge with abacavir.
    Walensky RP; Goldberg JH; Daily JP
    AIDS; 1999 May; 13(8):999-1000. PubMed ID: 10371187
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.
    El-Sahly HM
    AIDS; 2004 Jan; 18(2):359-60. PubMed ID: 15075569
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
    Frissen PH; de Vries J; Weigel HM; Brinkman K
    AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypersensitivity reactions due to abacavir.
    Newsline People AIDS Coalit N Y; 1998 Feb; ():35-6. PubMed ID: 11367446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No rechallenge for abacavir.
    AIDS Patient Care STDS; 2004 Dec; 18(12):737. PubMed ID: 15669129
    [No Abstract]   [Full Text] [Related]  

  • 10. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

  • 11. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
    Bellagamba R; Tommasi C; De Marco M; Narciso P
    J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
    [No Abstract]   [Full Text] [Related]  

  • 12. Management protocol for abacavir-related hypersensitivity reaction.
    Clay PG; Rathbun RC; Slater LN
    Ann Pharmacother; 2000 Feb; 34(2):247-9. PubMed ID: 10676833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual clinical presentation of hypersensitivity reaction to abacavir.
    Aquilina C; Mularczyk M; Lucas F; Viraben R
    AIDS; 2003 Nov; 17(16):2403-4. PubMed ID: 14571198
    [No Abstract]   [Full Text] [Related]  

  • 14. Abacavir hypersensitivity reaction.
    Hewitt RG
    Clin Infect Dis; 2002 Apr; 34(8):1137-42. PubMed ID: 11915004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
    de la Rosa R; Harris M; Uyeda L; Goodison K; Keown P; Montaner JS
    AIDS; 2004 Feb; 18(3):578-9. PubMed ID: 15090818
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment: Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Oct; 42(10):1519-20; author reply 1520-1. PubMed ID: 18780810
    [No Abstract]   [Full Text] [Related]  

  • 17. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ; Sullivan JR; Knowles SR; Shear NH
    AIDS; 2002 Nov; 16(16):2223-5. PubMed ID: 12409746
    [No Abstract]   [Full Text] [Related]  

  • 18. Newly approved abacavir to carry hypersensitivity warning.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(4):304. PubMed ID: 10690211
    [No Abstract]   [Full Text] [Related]  

  • 19. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 20. Abacavir at last.
    Gilden D
    GMHC Treat Issues; 1998 Mar; 12(3):9. PubMed ID: 11365394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.